How will the recall of API valsartan impact patients and the industry?

Altavant Sciences has dosed the first patient in the ELEVATE 1 trial of its lead candidate rodatristat ethyl to treat adults with pulmonary arterial hypertension (PAH).

The proof-of-concept Phase IIa study has been designed to provide safety, target engagement, and biomarker information, which will be used to perform a comprehensive Phase IIb efficacy study of the candidate.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The double-blind, placebo-controlled, multi-centre ELEVATE 1 trial will determine the safety, tolerability, pharmacokinetics (PK), and biomarker pharmacodynamics of rodatristat ethyl.

Altavant will enrol about 36 adults with PAH in the ELEVATE 1 trial. Eligible subjects will be randomised 2:1 to receive rodatristat ethyl or placebo twice daily for six weeks and will be evaluated for primary and secondary endpoints of safety and PK.

ELEVATE 1 will also evaluate the effect of the candidate on biomarkers of target engagement and on several exploratory efficacy measures.

Altavant Sciences CEO William Symonds said: “Initiating the ELEVATE 1 study is a significant milestone for Altavant, and represents our commitment to the rare respiratory disease community and our approach to patient-centric, transparent clinical development.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

“Our goal for ELEVATE 1 is to establish proof-of-concept for this new mechanism in PAH, which we believe could halt or reverse the pulmonary vascular remodelling characteristic of the disease.”

Tryptophan hydroxylase (TPH) inhibitor rodatristat ethyl has been designed to reduce the body’s peripheral production of serotonin.

It is capable of lowering circulating serotonin levels and may halt or reverse the pathology of diseases driven by excessive serotonin production, such as PAH, idiopathic pulmonary fibrosis (IPF), and sarcoidosis.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
YPrime won the Innovation award for AI in Clinical Trials and the Environmental award for Sustainable Trials, thanks to its eCOA, IRT and eConsent platforms. Explore how purpose-built AI, paperless workflows and circular hardware practices are reshaping timelines, data quality and ESG performance in clinical research.

Discover the Impact